Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned.
35 Stocks Moving In Friday’s Mid-Day Session
Gainers
Biomerica, Inc. (NASDAQ: BMRA) shares climbed 38.3% to $6.23. Biomerica entered into a Supplier Agreement with Walmart to sell its EZ Detect colorectal disease screening test within the Walmart retail system.
Why Are Omeros Shares Plunging On Friday?
The FDA has identified deficiencies regarding Omeros Corporation’s (NASDAQ:OMER) marketing application of narsoplimab for hematopoietic stem cell transplant-associated…
Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Rises In September
Following the market opening Friday, the Dow traded up 0.49% to 34,010.27 while the NASDAQ fell 0.23% to 14,415.00. The S&P also rose, gaining 0.16% to 4,314.50.
JP Morgan Initiates Coverage On Omeros with Neutral Rating, Announces Price Target of $15
JP Morgan analyst Eric Joseph initiates coverage on Omeros (NASDAQ:OMER) with a Neutral rating and announces Price Target of $15.
Looking Into Omeros’s Return On Capital Employed
According to data from Benzinga Pro, during Q2, Omeros's (NASDAQ:OMER) reported sales totaled $28.82 million. Despite a 21.55% increase in earnings, the company posted a loss of $24.02 million.
Omeros: Q2 Earnings Insights
Shares of Omeros (NASDAQ:OMER) moved higher in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 24.59% year over year to ($0.46), which beat the estimate of ($0.57).
Omeros Q2 EPS $(0.46) Beats $(0.57) Estimate, Sales $28.82M Beat $24.27M Estimate
Omeros (NASDAQ:OMER) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.57) by 19.3 percent. This is a 24.59 percent increase over losses of $(0.61) per share from the same